Evidence map›Paper›PMID 32461567›Full record

ArticleEye (London, England)2021

Response to 'Comment on: "Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases"'.

Ivan Seah, Xin Xin Zhao, Qianyu Lin, Zengping Liu, Steven Zheng Zhe Su, Yew Sen Yuen, Walter Hunziker, Gopal Lingam, Xian Jun Loh, Xinyi Su

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Ivan SeahDepartment of Ophthalmology, National University Hospital Singapore, Singapore, Singapore.ORCID http://orcid.org/0000-0001-7843-1917
Xin Xin ZhaoInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Qianyu LinInstitute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Zengping LiuDepartment of Ophthalmology, Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore.
Steven Zheng Zhe SuLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Yew Sen YuenDepartment of Ophthalmology, National University Hospital Singapore, Singapore, Singapore.
Walter HunzikerInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID http://orcid.org/0000-0002-5265-4933
Gopal LingamDepartment of Ophthalmology, National University Hospital Singapore, Singapore, Singapore. gopal_lingam@nuhs.edu.sg.ORCID http://orcid.org/0000-0001-9130-5712
Xian Jun LohInstitute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore. lohxj@imre.a-star.edu.sg.
Xinyi SuDepartment of Ophthalmology, National University Hospital Singapore, Singapore, Singapore. xinyi_su@nuhs.edu.sg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biocompatible MaterialsRetinal DiseasesBevacizumabHumansBevacizumabBiocompatible Materials

Identifiers

PMID32461567
PMCPMC8027024

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.